


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo

英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

**VOLUNTARY ANNOUNCEMENT
INSILICO MEDICINE REPORTS PRELIMINARY POSITIVE
FIRST-IN-HUMAN CLINICAL TRIAL DATA
FOR ISM6331 DESIGNED USING GENERATIVE AI
IN MESOTHELIOMA AND OTHER SOLID TUMORS AT ESMO 2026**

This announcement is made by InSilico Medicine Cayman TopCo (the “**Company**”, together with its subsidiaries, the “**Group**” or “**InSilico Medicine**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company has announced preliminary promising first-in-human Phase I clinical trial data for ISM6331, an investigational oral pan-TEAD inhibitor designed using Chemistry42 generative AI platform. As of August 14, 2026, the data cut-off date, among response-evaluable participants with mesothelioma, the objective response rate (ORR) was 40.0% at 130 mg once daily, and the disease control rate (DCR) across the 30-130 mg dose range was 68.2% at the first tumor assessment. Findings were presented as a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

In the ongoing Phase I clinical study (NCT06566079; data cutoff date: August 14, 2026; N=36 enrolled across 15-130 mg; median prior lines 2, range 1-12; dose escalation ongoing), across 30-130 mg, mesothelioma ORR was 18.2% (four of 22 response-evaluable participants), with responses at 30, 50, and 130 mg. Three of four responders showed responses at the first Week-8 scan. Three of four partial responses were ongoing as of the data cut-off date, including one lasting approximately one year.

Early signals of anti-tumor activity beyond mesothelioma included target-lesion shrinkage in heavily pretreated non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) (seven and eight prior lines respectively) and stable disease (SD) beyond four months in epithelioid hemangioendothelioma (EHE) and colorectal cancer (CRC).

No dose-limiting toxicity (DLT) was reported from 15 mg through 130 mg, and no treatment-related adverse events (TRAEs) led to permanent discontinuation. TRAEs were mostly low grades (Grade 1 or 2); Grade 3 TRAEs occurred in 8.3% of participants, including asymptomatic amylase and lipase increase, fatigue and drug dermatitis; treatment-related proteinuria (adverse event of special interest) occurred in 11.1% of participants, all Grade 1 or 2 and reversible. Sustained reductions in circulating cellular communication network factor 2 (CCN2) support TEAD pathway engagement; terminal half-life of approximately 18-32 hours supports continuous once-daily dosing.

About ISM6331

ISM6331 is an investigational oral non-covalent pan-TEAD inhibitor designed to block TEAD-dependent transcription downstream of the Hippo pathway and is being evaluated in a global multicenter Phase I clinical study in advanced solid tumors (NCT06566079). The novel, non-covalent structure of ISM6331 was guided by Chemistry42's structure-based drug design strategy.

In preclinical studies, ISM6331 demonstrated broad anti-tumor efficacy, potent activity at low doses, and a favorable safety profile with favorable ADMET characteristics. In 2024, ISM6331 was granted orphan drug designation by the FDA for the treatment of mesothelioma. In January 2025, the first patient was dosed in the global multicenter Phase I clinical trial of ISM6331. In July 2026, ISM6331 received FDA Fast Track Designation.

Forward-Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, October 27, 2026

As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Chuen Yan Leung, Ph.D. as non-executive director; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.